Finance

Lists
Q2 2027 earnings
See results
524516:BOM
Bacil Pharma Ltd
21,41 INR
-2,46%
(-0,54) 1D
16-окт., 15:57:51 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524516...
Open
20,86 INR
High
21,95 INR
Low
20,86 INR
Mkt. cap
307,30 млн
Avg. vol.
48,73 миң
Volume
1,20 миң
P/E ratio
38,42
52-wk high
61,80 INR
52-wk low
10,65 INR
EPS
0,56 INR
No. of employees
2
Open
20,86 INR
High
21,95 INR
Low
20,86 INR
Mkt. cap
307,30 млн
Avg. vol.
48,73 миң
Volume
1,20 миң
P/E ratio
38,42
52-wk high
61,80 INR
52-wk low
10,65 INR
EPS
0,56 INR
No. of employees
2
News stories
From web sources and news partners
About Bacil Pharma Ltd
CEO-
Employees2
Founded1987
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 14-окт.
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
918,00 миң / -
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
-
-
-
918,00 миң
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
60,00 миң
109,00 миң
72,00 миң
72,00 миң
Operating expense
253,00 миң
743,00 миң
227,00 миң
593,00 миң
Total operating expenses
253,00 миң
743,00 миң
227,00 миң
593,00 миң
Operating income
-253,00 миң
-743,00 миң
-227,00 миң
325,00 миң
Other non operating income
645,00 миң
-1,22 млн
891,00 миң
-
EBT including unusual items
392,00 миң
390,00 миң
664,00 миң
-299,00 миң
EBT excluding unusual items
392,00 миң
390,00 миң
664,00 миң
-299,00 миң
Income tax expense
-
-7,95 млн
825,00 миң
423,00 миң
Effective tax rate
-
-2 037,95%
124,25%
-141,47%
Other operating expenses
193,00 миң
634,00 миң
155,00 миң
521,00 миң
Net income
392,00 миң
8,34 млн
-161,00 миң
-722,00 миң
Net profit margin
-
-
-
-78,65%
Earnings per share
-
-
-
-
Interest and investment income
-
2,35 млн
-
-
Interest expense
-
-
-
-624,00 миң
Net interest expenses
-
2,35 млн
-
-624,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-251,25 миң
-741,25 миң
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору